- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03861091
Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT
A Randomized Clinical Trial of Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT
This is a double blind randomized controlled study investigating the efficacy of a single dose of 150 mg risedronate (a bone anti-resorptive) vs a single dose of placebo given prior to SBRT for peripheral lung tumors that are within 2 cm of the chest wall. Our hypothesis is that the use of a single dose of 150 mg risedronate will eliminate or greatly reduce the rapid bone loss that occurs with radiation induced early osteoclast recruitment/activation.
Patients will be given either a single dose of 150 mg risedronate or placebo at the time of their treatment mapping "simulation" CT scan. Typically, radiation treatments begin at 1 - 3 weeks following this mapping scan, as each treatment plan requires detailed physics calculations and quality assurance checks.
All CT imaging referenced below is performed as a routine standard of care surveillance and is necessary for cancer treatment follow-up. These chest CT scans that are utilized in this research protocol would be performed every 3 months regardless of inclusion on this trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
2.1 Primary Objective(s)
The primary objective is to assess the percent change in bone mean cortical thickness within regions of bone receiving 30 Gy or more at 3 months after SBRT. The % change in mean cortical thickness will be compared between patients who received risedronate and those who received placebo.
2.2 Secondary Objective(s)
In addition to the primary objective, the investigators will further analyze the remaining routine follow-up chest CT scans, for mean cortical thickness change in regions of bone that received 0 - 10 Gy, >10 - 20 Gy, > 20 - 30 Gy, > 30 - 40 Gy, and > 40 Gy at all time points including 3 months, 6 months, 9 months, and 12 months. These scans are standard of care and would be performed regardless of inclusion on this trial. This will allow us to determine the potential persistence of effects from SBRT and bisphosphonate use.
The investigators will assess and compare the incidence and grade (per modified CTCAE v.5) of radiation induced chest wall pain within the radiation treatment portal (within the 50% isodose line) at time of each routine follow up visit (3 months, 6 months, 9 months, and 12 months post SBRT). The purpose of utilizing a placebo and double-blind design is that chest wall pain is a subjective finding. Furthermore, it is unclear if chest wall pain from radiation is directly due to bone damage, nerve damage, muscle irritation, or a combination of all of these factors. The use of placebo will help us reduce the potential for bias in pain assessment.
The investigators will assess and compare the incidence of rib and vertebral fractures (as noted on CT imaging) that occur within 12 months of irradiation and are within the radiation treatment field. The radiation treatment field will be defined as within the 50% isodose line.
The urine concentration of an osteoclast-specific biomarker, urinary N-telopeptide (NTX) indicating osteoclast activity will be assessed prior to SBRT and at each routine follow up visit (at 3 months, 6 months, 9 months, and 12 months post SBRT).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- High Point Regional Medical Center
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be 18 years or older, but there is no upper limit on age of inclusion.
- Patients must have a peripheral lung tumor that is amenable to SBRT as determined by the treating radiation oncologist. To be classified as a peripheral lung tumor, the tumor edge (the edge of the gross tumor volume or GTV in radiation treatment planning software) must be within 2 cm of the chest wall. This is determined by the treating radiation oncologist. The chest wall is defined as the chest wall musculature or ribs/vertebrae immediately adjacent to the lungs.
- Patients must have ECOG status of 0-3
- Patients must have a life expectancy of at least 3 months as determined by the treating radiation oncologist.
- Patients must have the ability to understand and the willingness to sign an IRB-approved informed consent document.
Exclusion Criteria:
Prior radiation to any part of the body including the lungs or thorax is not an exclusion criteria
- Tumor edge is greater than 2 cm from the chest wall. The edge of tumor is the edge of the gross tumor volume or GTV as defined in radiation treatment planning software. This is determined by the treating radiation oncologist.
- Tumors that are expected to require more than 10 fractions of radiation as determined by the treating radiation oncologist.
- History of using bone anti-resorptive agents including bisphosphonates or RANK-L inhibitors within the last 1 year.
- Inability to stand or sit upright for at least 30 minutes, which is necessary for ingestion of risedronate.
- Hypocalcemia defined as serum total calcium lower than 8.5 mg/dL on most recent bloodwork that is within 3 months of administration of study drug/placebo.
- Severe renal impairment (EGFR <30 mL/min) on most recent bloodwork that is within 3 months of administration of study drug/placebo.
- Known allergy to risedronate or other bisphosphonates
- Surgery affecting the bone or dental operations within the last 6 months. This will be explicitly asked and documented in the EMR by treating radiation oncologist.
- Dental operations do not include routine cleaning or cavity fillings
- Dental operations that exclude patients refer to any manipulation of mandible.
- Positive urine pregnancy test in women of child bearing potential within 1 week of registration. Pregnant women are excluded from this study because radiation has clear teratogenic and potentially abortifacient risks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Risedronate
Risedronate 150 mg given once 7-21 days prior to initiation of SBRT
|
Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
Other Names:
|
Placebo Comparator: Matching Placebo
Matching placebo, dose not applicable given once 7-21 days prior to initiation of SBRT
|
Dose not applicable, given once 7-21 days prior to initiation of SBRT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Mean Cortical Thickness
Time Frame: At baseline and at 3 months post radiation
|
The primary outcome measure is the percent change in mean cortical thickness (C.Th) of bones receiving 30 Gy or more at 3 months post SBRT, when compared to pre-SBRT cortical thickness
|
At baseline and at 3 months post radiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
4 Time Points Assessing Change in Mean Cortical Thickness of Bones
Time Frame: At baseline, 3 months, 6 months, 9 months and 12 months post radiation
|
The percent change in mean C.Th of bones will be assessed in regions of bone that received 0 - 10 Gy, >10 - 20 Gy, > 20 - 30 Gy, > 30 - 40 Gy, and > 40 Gy at all time points including 3 months, 6 months, 9 months, and 12 months.
|
At baseline, 3 months, 6 months, 9 months and 12 months post radiation
|
Number of Participants With Chest Wall Pain
Time Frame: At baseline, 3 months, 6 months, 9 months and 12 months post radiation
|
Chest wall pain incidence and grade will be collected as per modified CTCAE v. 5 within the within the 50% isodose line.
Appendix K. Below we report numbers with any chest wall pain of grades 3+ over the year of followup.
|
At baseline, 3 months, 6 months, 9 months and 12 months post radiation
|
Number of Participants With Rib and Vertebral Fracture
Time Frame: At 12 months post radiation
|
Incidence of rib and vertebral fractures (as noted on CT imaging) that occur within 12 months of irradiation and are within the within 50% isodose line.
|
At 12 months post radiation
|
Urine Concentration at 4 Time Points
Time Frame: At 3 months, 6 months, 9 months and 12 months post radiation
|
The urine concentration of an osteoclast-specific biomarker, urinary N-telopeptide (U-NTX) indicating osteoclastic activity will be assessed prior to SBRT and at each routine follow up visit (at 3 months, 6 months, 9 months, and 12 months post SBRT).
|
At 3 months, 6 months, 9 months and 12 months post radiation
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michael Farris, MD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Risedronic Acid
Other Study ID Numbers
- IRB00056835
- P30CA012197 (U.S. NIH Grant/Contract)
- CCCWFU99518 (Other Identifier: Wake Forest Baptist Comprehensive Cancer Center)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Neoplasm
-
National Cancer Institute (NCI)RecruitingLocally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditionsUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedPrimary Malignant Neoplasm of Lung | Primary Malignant Neoplasm of Gastrointestinal TractUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung Carcinoma | Lung Neoplasm | Malignant Lung NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
Mirati Therapeutics Inc.RecruitingMetastatic Cancer | Advanced Cancer | Malignant Neoplasm of LungKorea, Republic of, United States, Turkey, France, Taiwan
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Jiangsu ShengDiYa Medicine Co., Ltd.Dongguan People's HospitalUnknownNonsquamous Nonsmall Cell Neoplasm of Lung
-
Spanish Lung Cancer GroupCompletedNonsquamous Nonsmall Cell Neoplasm of LungSpain
-
SanofiTerminatedBreast Cancer | Gastric Cancer | Neoplasm | Lung Neoplasm Malignant | Neoplasm MalignantBelgium, Korea, Republic of, United States, Taiwan, Spain, France
-
Rgene CorporationAmerican BriVision CorporationNot yet recruitingNonsquamous Nonsmall Cell Neoplasm of LungTaiwan
Clinical Trials on risedronate
-
Hanlim Pharm. Co., Ltd.Completed
-
Warner ChilcottCompletedPostmenopausal Women With OsteoporosisSpain, Australia, Belgium, Denmark, Finland, Italy, Poland, Sweden
-
SanofiProcter and GambleCompleted
-
Montefiore Medical CenterCompletedRenal Transplant OsteodystrophyUnited States
-
UConn HealthProctor and Gamble/AventisCompletedProstate CancerUnited States
-
University of OklahomaNational Center for Research Resources (NCRR)CompletedDiabetes Mellitus, Adult OnsetUnited States
-
M.D. Anderson Cancer CenterProcter and GambleCompleted
-
Columbia UniversityAlliance for Better Bone HealthCompletedOsteoporosisUnited States
-
Hanlim Pharm. Co., Ltd.CompletedOsteoporosisKorea, Republic of
-
PfizerCompletedDyslipidemia | HypercholesterolemiaUnited States